Please see attached important updates regarding CDC's discontinuation of its distribution of intravenous artesunate for treatment of severe malaria in the U.S. on September 30, 2022.
This information has been broadcast to: Community Health Centers (FQHCs); Long-term Care; Health Care Facilities / Other; Health Care Organizations; Health Care Providers; Hospital Staff Directory; Hospital CEOs; Hospital Emerg Preparedness Coords; Hospital ER Medical Directors; Hospital Infection Control Practitioners; Hospital Medical Directors; Hospital Nursing Directors; Hospital Patient Safety Liaisons; Hospital Quality Liaisons; Hospital Security Directors; ICU Administrator; Lab Director; Hospitals / Acute Care; Hospitals / Other; Hospitals / Veterans; Pharmaceutical Suppliers; Local Boards of Health; NJDOH Staff; NJLINCS and Local Contacts; NJLINCS Community; Public Health Associations; Public Health Council; Public Health Sector